MBX Biosciences, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBX research report →
Companymbxbio.com
MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
- CEO
- Peter Kent Hawryluk
- IPO
- 2000
- Employees
- 43
- HQ
- Carmel, IN, US
Price Chart
Valuation
- Market Cap
- $1.06B
- P/E
- -16.90
- P/S
- 0.00
- P/B
- 3.34
- EV/EBITDA
- -10.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.50%
- ROIC
- -22.54%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-86,971,000 · -40.45%
- EPS
- $-2.38 · -28.65%
- Op Income
- $-98,055,000
- FCF YoY
- -47.38%
Performance & Tape
- 52W High
- $45.85
- 52W Low
- $9.43
- 50D MA
- $31.43
- 200D MA
- $26.48
- Beta
- 0.78
- Avg Volume
- 577.80K
Get TickerSpark's AI analysis on MBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Azoulay Salomon | other | 55,000 |
| May 8, 26 | Azoulay Salomon | other | 55,000 |
| May 8, 26 | Azoulay Salomon | other | 15,003 |
| May 8, 26 | Azoulay Salomon | other | 15,003 |
| May 8, 26 | Azoulay Salomon | sell | 15,003 |
| May 8, 26 | Azoulay Salomon | sell | 55,000 |
| May 6, 26 | Azoulay Salomon | sell | 231 |
| May 6, 26 | Hawryluk P. Kent | sell | 607 |
| May 1, 26 | Hoerter Steven L. | other | 74,249 |
| May 1, 26 | Hoerter Steven L. | other | 11,938 |
Our MBX Coverage
We haven't published any research on MBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MBX Report →